Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines

Journal of Biomedical Science

Volumn 18, Issue 1, 2011, Pages

  Peng, Shiwen ^a   Monie, Archana ^a   Pang, Xiaowu ^b   Hung, Chien Fu ^a   Wu, T C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b University College of Dentistry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN E7; VADIMEZAN; VIRUS DNA; WART VIRUS VACCINE; 5,6 DIMETHYLXANTHENONEACETIC ACID; 5,6-DIMETHYLXANTHENONEACETIC ACID; ANTINEOPLASTIC AGENT; CANCER VACCINE; DNA VACCINE; XANTHONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VACCINATION; ANIMAL; C57BL MOUSE; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; IMMUNOLOGY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRUS VACCINES; VACCINES, DNA; XANTHONES;

EID: 79952321425     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-18-21     Document Type: Article

References (21)

1. DNA vaccines. JJ Donnelly JB Ulmer MA Liu, Life sciences 1997 60 163 172 10.1016/S0024-3205(96)00502-4 9000640
2. DNA vaccines: immunology, application, and optimization. S Gurunathan DM Klinman RA Seder, Annual review of immunology 2000 18 927 974 10.1146/annurev.immunol.18.1.927 10837079 (Pubitemid 30365401)
3. Improving DNA vaccine potency via modification of professional antigen presenting cells. CF Hung TC Wu, Current opinion in molecular therapeutics 2003 5 20 24 12669466
4. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. SW Tsen AH Paik CF Hung TC Wu, Expert review of vaccines 2007 6 227 239 10.1586/14760584.6.2.227 17408372 (Pubitemid 46607458)
5. Calreticulin, a Ca2+-binding chaperone of the endoplasmic reticulum. P Gelebart M Opas M Michalak, The international journal of biochemistry & cell biology 2005 37 260 266 (Pubitemid 39330186)
6. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. WF Cheng CF Hung CY Chai KF Hsu L He M Ling TC Wu, The Journal of clinical investigation 2001 108 669 678 11544272 (Pubitemid 32906195)
7. Comparison of HPV DNA vaccines employing intracellular targeting strategies. JW Kim CF Hung J Juang L He TW Kim DK Armstrong SI Pai PJ Chen CT Lin DA Boyd TC Wu, Gene Ther 2004 11 1011 1018 10.1038/sj.gt.3302252 14985791 (Pubitemid 38923625)
8. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. S Peng H Ji C Trimble L He YC Tsai J Yeatermeyer DA Boyd CF Hung TC Wu, J Virol 2004 78 8468 8476 10.1128/JVI.78.16.8468-8476.2004 15280455 (Pubitemid 39025112)
9. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. TW Kim JH Lee CF Hung S Peng R Roden MC Wang R Viscidi YC Tsai L He PJ Chen DA Boyd TC Wu, J Virol 2004 78 4638 4645 10.1128/JVI.78.9.4638-4645.2004 15078946 (Pubitemid 38501085)
10. Small molecule vascular disrupting agents: potential new drugs for cancer treatment. SX Cai, Recent Pat Anticancer Drug Discov 2007 2 79 101 10.2174/157489207779561462 18221055 (Pubitemid 46723154)
11. Antivascular therapy of cancer: DMXAA. BC Baguley, The lancet oncology 2003 4 141 148 10.1016/S1470-2045(03)01018-0 12623359 (Pubitemid 36322304)
12. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. MJ McKeage P Fong M Jeffery BC Baguley P Kestell M Ravic MB Jameson, Clin Cancer Res 2006 12 1776 1784 10.1158/1078-0432.CCR-05-1939 16551862
13. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. KY Lin FG Guarnieri KF Staveley-O'Carroll HI Levitsky JT August DM Pardoll TC Wu, Cancer research 1996 56 21 26 8548765 (Pubitemid 26010379)
14. DNA Vaccines Encoding Ii-PADRE Generates Potent PADRE-specific CD4(+) T-Cell Immune Responses and Enhances Vaccine Potency. CF Hung YC Tsai L He TC Wu, Mol Ther 2007 15 1211 1219 17356542 (Pubitemid 46813626)
15. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. TC Wu FG Guarnieri KF Staveley-O'Carroll RP Viscidi HI Levitsky L Hedrick KR Cho JT August DM Pardoll, Proc Natl Acad Sci USA 1995 92 11671 11675 10.1073/pnas.92.25.11671 8524826 (Pubitemid 26014175)
16. Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid. E Moilanen LL Thomsen DW Miles DW Happerfield RG Knowles S Moncada, British journal of cancer 1998 77 426 433 10.1038/bjc.1998.68 9472639 (Pubitemid 28044047)
17. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. KS Peggs SA Quezada JP Allison, Clinical and experimental immunology 2009 157 9 19 10.1111/j.1365-2249.2009.03912.x 19659765
18. The role of nitric oxide in cancer. W Xu LZ Liu M Loizidou M Ahmed IG Charles, Cell research 2002 12 311 320 10.1038/sj.cr.7290133 12528889 (Pubitemid 135708343)
19. Nitric oxide and T helper cell immunity. RC van der Veen, International immunopharmacology 2001 1 1491 1500 10.1016/S1567-5769(01)00093-5 11515814 (Pubitemid 32622793)
20. Control of Cervicovaginal HPV-16 E7-Expressing Tumors by the Combination of Therapeutic HPV Vaccination and Vascular Disrupting Agents Human gene therapy (in press). Q Zeng A Monie S Peng C-F Hung T-C Wu, 2010
21. Regulatory T cells and inhibitory cytokines in autoimmunity. M Bettini DA Vignali, Current opinion in immunology 2009 21 612 618 10.1016/j.coi.2009.09. 011 19854631